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ABSTRACT
Background: Hyponatremia is the most common electrolyte disorder among
hospitalized patients. Controversies still exist over the relationship between
hyponatremia and outcomes of hospitalized patients.
Methods: To analyze the association of low serum sodium levels at hospital
admission with in-hospital mortality and patient disposition and to compare the
distribution of the risk of death associated with hyponatremia across the lifespan
of hospitalized patients, we conducted an observational study of 2.3 million
patients using data extracted from the Cerner Health Facts database between
2000 and 2014. Logistic regression models were used in the analyses.
Results: 14.4% of hospitalized patients had serum sodium levels [Na] <135
mEq/L. In adjusted multinomial logistic regression analysis, we found that the risk
of in-hospital mortality significantly increases for [Na] levels < 135 or ≥143 to
≤145 mEq/L compared to the reference interval of 140 to <143 mEq/L. We
observed similar trends for the relationship between [Na] levels and discharge to
hospice or to a nursing facility. We demonstrated that younger age groups (18 to
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<45, 45 to <65) had a higher risk of in-hospital mortality compared to older age
groups (65 to <75, ≥75) for [Na] levels <130 mEq/L or 143 to ≤145 mEq/L.
Conclusions: Hyponatremia is common among hospitalized patients and is
independently associated with in-hospital mortality, discharge to hospice or to a
nursing facility. The risk of death and other outcomes was more evident for [Na]
<135 mEq/L. The mortality associated with low [Na] was significantly higher in
younger versus older patients.
Keywords: Hyponatremia; Hospitalization; Outcomes; In-hospital mortality;
Discharge disposition; Age
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CHAPTER 1
INTRODUCTION

Hyponatremia is the most frequent electrolyte disorder among hospitalized
patients (1, 2). It is associated with poor outcomes such as increased mortality,
prolonged length of stay in the hospital, and increased healthcare costs (3-11). In
a retrospective study by Nzerue et al that included 5994 hospitalized patients
with hyponatremia between 1997 and 2001, for the 168 patients with severe
hyponatremia defined as serum sodium [Na] levels < 115 mEq/L, the mortality
rate was 20%. They also found that severe hyponatremia was significantly
associated with in-hospital mortality (3). In another retrospective study by Clayton
et al conducted over a period of six months, 108 hospitalized patients with
hyponatremia defined as serum [Na] levels ≤ 125 mEq/L, the in-hospital mortality
rate was also 20% (4). Moreover, in a prospective case control study by Gill et al
performed over a six-month period that included 104 hospitalized patients with
severe hyponatremia (<125 mEq/L) and 104 randomly chosen patients with
normonatremia (>135 mEq/L), the mortality rate was 27% in the severe
hyponatremia group compared to 9% in the normonatremia group. They found
that severe hyponatremia in hospitalized patients is associated with significantly
increased mortality and prolonged length of stay in the hospital (5). Another
retrospective cohort study by Zilberberg et al that included 198,281 hospitalized
from 39 US hospitals between 2004 and 2005, hyponatremia defined as sodium
<135 mEq/L was independently associated with increased in-hospital mortality,
increased need for ICU admission, increased length of stay in the hospital, and
1

increased hospital costs compared to those without hyponatremia (6). In a metaanalysis by Corona et al, that included 46 studies, hyponatremia was significantly
associated with prolonged length of stay in the hospital and increased risk of
readmission after hospitalization. They also showed that hyponatremia
contributed to approximately $3,000 higher in hospital costs compared to patients
without hyponatremia (10) In another study by Amin et al, hyponatremia was
associated with an 8.2% increase in the total hospital admission costs and a 15%
increase in the 30 day hospital readmission rates (11).

Mechanism of the Association Between Hyponatremia and Mortality:
Different mechanisms have been proposed to explain the association between
hyponatremia and mortality (12, 13). These mechanisms explain whether
hyponatremia is a direct cause of mortality or the underlying severe disease is
responsible for the mortality while hyponatremia is only a complication of this
severe disease. The first mechanism suggests that acute hyponatremia, if
untreated appropriately, will cause severe brain edema, encephalopathy, and
brain herniation, which leads to death. Although is it very critical to recognize and
treat patients with acute hyponatremia, this mechanism does not fully explain the
relation between hyponatremia and mortality. The second mechanism suggests
that hyponatremia is only a sign of underlying serious medical conditions. The
high mortality rates in patients with advanced heart failure or cirrhosis who have
hyponatremia can be explained by this mechanism. In the third mechanism, it is
postulated that hyponatremia has an additive effect on the increase in mortality.
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Comorbid conditions can cause increased mortality alone and the development
of hyponatremia. Hyponatremia on the other hand, can further increase the risk
of mortality independent of the underlying disease. This mechanism can be
justified by the fact that multiple studies found an independent association
between hyponatremia and the risk of in-hospital mortality even after adjusting
for potential confounding factors including the different comorbid conditions.

Defining the Exact Level of Hyponatremia That is Associated With Poor
Outcomes:
Hyponatremia is conventionally defined as having a serum [Na] <135 mEq/L.
However, despite the wide recognition of this definition of hyponatremia, different
cutoff points have been used by the various groups who have investigated the
outcomes of hyponatremia in hospitalized patients (3, 5-9, 14, 15). Hence, there
are large variations in the prevalence of hyponatremia that range from 5.5% to
38% (6-9, 14). Few studies have demonstrated harm associated with mild
hyponatremia (130-134mEq/L) (7) or even a low-normal range of conventional
normonatremia (<138 mEq/L) (8, 9). This has led some investigators to argue
that the current definition of hyponatremia should be reevaluated (8). For
example, in a prospective cohort study by Waikar et al that included 98,411
hospitalized patients at two teaching hospitals between 2000 and 2003,
hyponatremia defined as serum [Na] <135 mEq/L was present in 14.5 % of
patients at hospital admission (7). The risk of mortality was evident in cases of
mild hyponatremia (130-134 mEq/L). Moreover, in a retrospective study Wald et
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al that included 53,236 hospitalizations between 2000-2007, a serum sodium
[Na] value <138 mEq/L, which is considered in the normal range, was
independently associated with increased mortality in hospitalized patients,
prolonged length of stay in the hospital, and discharge to a short or long term
care facility (8). However, in this one-center study, the authors emphasized the
need for multiple center studies to confirm these findings (8). Furthermore, in a
retrospective study by Balling et al that included 2960 hospitalized patients
between 1998-1999, hyponatremia, defined as a serum sodium [Na] below 137
mEq/L, was associated with greater mortality (27.5% versus 17.7%) and longer
hospital stay compared to patients with normonatremia (Na ≥ 137 mEq/L) (9).
However, in this one center study, they did not adjust for glucose levels in the
analysis, and this may have resulted in overestimation of the prevalence of
hyponatremia (9).
There are also conflicting reports regarding whether mortality continues to
increase as hyponatremia worsens (8, 16, 17). In the study by Wald et al, the
mortality due to hyponatremia continued to increase with the decrease in serum
[Na] levels (8). However, in a retrospective study by Chawla et al, that included
45,693 hospitalized patients from a single community teaching hospital between
1996 and 2007, the in-hospital mortality increased as serum sodium fell from 134
to 120 mEq/L (16). However, for serum sodium levels below 120 mEq/L, the
trend is reversed, and the mortality rate progressively decreased. Moreover, in
the study by Holland-bill et al that included 279,508 hospitalized patients from the
Danish National Patient Registry (DNPR) between 2006 and 2011 (17), the risk
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of mortality increased as the serum [Na] decreased, but when [Na] values
dropped to <132 mEq/L, there was no further increase in mortality. Despite that,
they were able to demonstrate that the mortality risk increased with worsening
hyponatremia when they performed a stratified analysis in patients with a primary
diagnosis of cancer, liver disease, respiratory disease, and sepsis.

Age and Hyponatremia:
Hyponatremia is very common in the elderly patient population. Studies have
shown that hyponatremia affects 11% of elderly people living in the community
(18) and 18% of the elderly living in nursing facilities (19). Elderly patients have
a higher propensity to develop hyponatremia due to several mechanisms. For
example, aging may lead to impairment in the concentration capacity of the
kidneys, and results in slower water excretion. Moreover, elderly patients
commonly use several medications that are known to cause hyponatremia such
as thiazide diuretics. Furthermore, elderly patients have a high prevalence of
medical conditions that predispose them to the development of hyponatremia
such as chronic congestive heart failure, chronic kidney disease, pneumonia,
neurological disease (stroke), and malignancy (20, 21).
Although some studies have shown an increase in mortality in older patients (>65
years) with hyponatremia (22-24), others showed that hyponatremia was not
associated with mortality compared to normonatremic patients in this elderly age
group (25, 26) and one study surprisingly showed that mortality was more
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prevalent in hospitalizations involving patients younger than 65 years compared
to patients older than 65 years (8).
Hyponatremia and Other Comorbidities:
In addition to hyponatremia being associated with poor outcomes in general
hospitalized patients, it is also prevalent in patients with different comorbidities
and predisposes them to increased risk to poor outcomes. For example, it occurs
in approximately 20% of patients with heart failure (27), 40% to 60% of patients
with liver cirrhosis (28), and 35% of patients with syndrome of inappropriate
antidiuretic hormone (SIADH) (29). In patients admitted to the hospital with acute
heart failure, hyponatremia at hospital admission was an independent predictor
for all-cause mortality and cardiovascular mortality (30). Moreover, in liver
cirrhosis, hyponatremia is significantly associated with increased morbidity
and mortality and affects survival post liver-transplant (31). Hence, the poor
outcomes may be more pronounced in some comorbidities than in others.
Reasons for Conducting the Study:
Most of the studies addressing the relationship between hyponatremia and
selected outcomes of hospitalized patients were single-center studies and did not
include a large diverse population of hospitalized patients. Others used the ICD-9
codes for the diagnosis of hyponatremia and did not have the laboratory values
of serum sodium levels, so they were not able to differentiate the impact of
hyponatremia among patients with varying sodium concentrations (11). Lastly,
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little is known about the association of hyponatremia with discharge disposition—
specifically, discharge to hospice and nursing facility.
To address this gap in our knowledge regarding the cutoff points of hyponatremia
associated with poor outcomes of hospitalized patients and the distribution of the
risk of death associated with hyponatremia across the lifespan of these patients,
we analyzed data on patients hospitalized between January 2000 and November
2014 derived from the Cerner Health Facts database.

7

CHAPTER 2
MATERIALS AND METHODS
Study Design, Data Source and Population Selection:
We conducted an observational study of patients hospitalized between January
2000 and November 2014 using the Cerner Health Facts database. Health Facts
is a national database that includes de-identified electronic health records (EHR)
information from over 600 hospitals and clinics in the United States. The study
was reviewed and approved by the University of New Mexico Institutional Review
Board (15-531; October 27, 2015). We included the index hospital admission
defined by the first inpatient encounter of any patient during the study period who
met the following inclusion criteria: 1) age ≥ 18 years, and 2) first serum sodium
[Na] levels drawn during 24 hours before admission. The second inclusion
criterion was chosen to reduce the possibility that the [Na] levels were affected
by any treatments or iatrogenic causes after hospital admission.
Information was gathered regarding patients’ demographics, co-morbidities,
causes for admission, laboratory studies and disposition status at hospital
discharge. The co-morbidities were identified using the International
Classification of Diseases, 9th Edition, Clinical Modification (ICD-9-CM) codes,
while the laboratory tests were identified using Logical Observation Identifiers
Names and Codes (LOINC).The Deyo-Charlson Co-morbidity Index (Deyo-CCI)
was also calculated (32). Deyo-CCI a widely used co-morbidity index adapted
from the Charlson co-morbidity index for administrative databases. The index
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uses ICD-9 codes to identify 17 co-morbidities which are assigned a score of 1,
2, 3, or 6. These scores are summed to yield the comorbidity score.
Since hyperglycemia is a hyperosmotic state affecting [Na] levels, we corrected
the [Na] levels by adding 1.6 mEq/L for each 100 mg/dL above 100 mg/dL of the
concomitantly measured serum glucose levels (33). After searching the literature
for cases of extreme hyponatremia or extreme hypernatremia (34-37), we
decided to exclude patients with [Na] values <90 or >201 mEq/L (Figure 1). We
further excluded patients with [Na] > 145 mEq/L and those with missing gender,
race and outcomes values. The final cohort available for analysis included
2,284,912 patients (Figure 1). Our primary outcomes were in-hospital mortality
(n=63,359) and discharge disposition of hospitalized patients. The discharge
dispositions included discharge to hospice (n=32,335), discharge to home
(n=1,739,780), discharge to nursing facility (n=274,755), discharge to short or
long term care hospital (n=91,703), rehabilitation (n=58,259), and left against
medical advice (n=24,721). Discharge to hospice, discharge to nursing facility,
and discharge to home were the main outcomes for discharge disposition.
Statistical Analyses:
We performed descriptive statistical analyses of the study cohort. Continuous
variables were summarized as means and standard deviations (SD) and were
compared using the student’s t test. Categorical variables were summarized as
percentages and were compared using the chi-square test.
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To evaluate which patient characteristics are associated with increased risk of
developing hyponatremia, we fitted a logistic regression model of the relation
between hyponatremia (<135 mEq/L vs ≥135 to ≤145 mEq/L) and the different
patient characteristics of interest including age, gender, race and selected
comorbidities (hypertension, myocardial infarction, coronary artery disease, heart
failure, diabetes mellitus (DM), peripheral vascular disease, chronic kidney
disease (CKD), end stage renal disease (ESRD), cirrhosis, chronic pulmonary
disease, chronic obstructive pulmonary disease (COPD), rheumatologic disease,
cerebrovascular disease, dementia, peptic ulcer disease, adrenal insufficiency,
hypothyroidism, depression, acquired immunodeficiency syndrome (AIDS),
hemiplegia, metastatic cancer, lung cancer, malignancy, pneumonia, sepsis,
syndrome of inappropriate antidiuretic hormone (SIADH), and urinary tract
infections (UTI). We adjusted for all these selected comorbidities in our analyses
as appropriate. In these analyses, Age was categorized into four different groups:
≥18 to <45, ≥45 to <65, ≥65 to <75, and ≥75 years old. We had 461,511
(20.20%) patients in the ≥18 to <45 group, 740,035 (32.40%) in the ≥45 to <65
group, 404,848 (17.70%) in the ≥65 to <75 group, and 678,518 (29.70%) in the
≥75 group.
We were interested in evaluating broader associations between [Na] and
outcomes. We therefore examined associations between quantitatively measured
[Na] and our study outcomes in two ways. First, in searching the literature, we
realized that the serum [Na] levels may have a nonlinear relation with the
different outcomes. Thus, to assess the flexible relation between the [Na] levels
10

and the different outcomes, we modeled this relationship using restricted cubic
splines method with five knots. These knots corresponded to the 5th, 27.5th, 50th,
72.5th, and 95th percentiles of the cohort’s [Na], and their values were 132, 136,
138, 140, and 143 mEq/L, respectively. Second, for simplicity in interpretation,
we categorized the [Na] levels into the following eight groups: 1: < 120; 2: ≥ 120
to < 125; 3: ≥ 125 to < 130; 4: ≥ 130 to < 135; 5: ≥ 135 to < 138; 6: ≥ 138 to <
140; 7: ≥ 143 to ≤ 145 mEq/L and we considered 0: ≥ 140 to < 143 mEq/L as the
reference group. Since we did not have a very large number of patients with
serum sodium levels <135 mEq/L, we decided to categorize the serum sodium
levels into 5 mEq/L intervals, as in other previous studies. However, since we
had a very large number of patients with serum sodium levels ≥ 135 mEq/L, we
let the restricted cubic spline knots guide us in this categorization. We used 138,
140 and 143 mEq/L to generate the categories. This led us to have an
approximately equal number of patients in the 135 to < 138, 138 to < 140, and
140 to < 143 mEq/L categories (approximately 600,000 patients) (Table 3).
Further, since our aim was to test the cutoff points of hyponatremia, we decided
to use 140 to <143 mEq/L as the reference group.
Since we were studying multiple nominal outcomes, performing a binary analysis
that reduces the 7 levels of outcomes down to two would potentially lead to loss
of information. Therefore, we decided to perform multinomial logistic regression
models as appropriate. These multinomial models allowed us to assess
associations of each outcome while accounting for the competing risks of the
others. In these models, we used “discharge to home” as the reference outcome.
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We used the restricted cubic spline terms in these models to generate predicted
probabilities across the continuum of [Na], and subsequently used these
predictions in order to visualize the patterns of the associations between [Na] and
the study outcomes (Figure 2). We used our defined [Na] categories in these
models to examine effects of the different intervals of hyponatremia and
normonatremia on our categorical outcomes (in-hospital mortality and patients’
disposition), both with or without accounting for the following potential
confounding covariates: age, gender, race, and the selected comorbidities
(specified above).
To further examine if age has a differential effect on the relation between [Na]
levels and the different outcomes, we first assessed this by using the restricted
cubic splines method in age stratified multinomial logistic regression models to
visualize the trends in the estimated probabilities (Figure 5, 6, 7, and 8). After
that, we modeled the interaction between each previously defined age group and
the aforementioned [Na] categories using multinomial logistic regression models
adjusting for age, gender, race and the selected comorbidities. We also did a
sensitivity analysis by performing all the aforementioned analyses while adjusting
for the Deyo-CCI instead of the selected comorbidities. The scores in the DeyoCCI ranged from 0 to 17. However, the number of patients that had a score of 12,
13, 14, 15, 16, or 17 was not very large, so we decided to group them into one
category. Therefore, we had 12 categories of the Deyo-CCI to adjust for.
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Subgroup Analysis:
To compare in-hospital mortality in different patient comorbidities, we modeled the
interaction between each comorbidity of interest and the presence or absence of
hyponatremia (<135 mEq/L) using logistic regression analysis. The covariate of
the model were the selected comorbidities specified earlier.
All the analyses were performed using Stata version 14.1(StataCorp LP, College
Station, TX).

13

CHAPTER 3
RESULTS
We found 2,698,978 patients who met our inclusion criteria (Figure 1). From this
cohort 210,526 patients lacking a concomitant serum glucose determination were
excluded from the study cohort. Our initial cohort of patients included 2,488,437
patients (Figure 1). The prevalence of hyponatremia (Na <135 mEq/L) at hospital
admission was 14.4% (357,418) (Table 1). The prevalence was 14.7% (365,698)
without adjusting for concomitant glucose. We noticed that after adjusting for the
concomitant glucose, only 2.3% (8,280) of patients who were initially classified as
having hyponatremia (365,698) were reclassified as normonatremic or
hypernatremic.
Those patients with hyponatremia (<135 mEq/L) were older than patients with
normonatremia (135-145 mEq/L), 64.1±18.1 vs. 60.8 ±19.1 years old (p<0.001).
Patients with hyponatremia had a higher overall Deyo-CCI score compared with
normonatremic patients 1.72±2.25 vs. 1.29±1.81, respectively, (p<0.001). Other
pertinent patient characteristics are summarized in Table 1.
After adjusting for age, gender, race and the selected comorbidities,
hyponatremia increased with increasing age. The odds ratios (ORs) [95 %
confidence interval, CI] of having hyponatremia for ages ≥45 to <65, ≥65 to <75
and ≥75 were 1.21 [1.20-1.23], 1.35 [1.33-1.37] and 1.56 [1.54-1.58],
respectively, compared to the reference age group ≥18 to <45 years old (Table
2).
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Figure 1. Flow Chart of the Sample Selection Process.
Serum sodium levels were corrected by adding 1.6 mEq/L for each 100 mg/dL above
100 mg/dL of the concomitantly measured serum glucose levels.
b
This number was used to calculate the prevalence of hyponatremia (Na < 135 mEq/L) at
hospital admission.
c
The final cohort available for analysis.
a
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Table 1. Characteristics of Hospitalized Patients With or Without Hyponatremia
Patient Characteristics

All Cohorta
n= 2,488,437

Normonatremia and Hyponatremia
patientsa (n=2,440,396)
Absence of
Presence of
Hyponatremia Hyponatremia (≥135
(<135 mEq/L), to ≤145 mEq/L),
n= 357,418
n=2,082,978

Age, mean (SD), y

61.5 (19)

64.1 (18.1)

60.8 (19.1)

Gender, %
Females
Males
N/A

54.29
45.69
0.02

53.98
46.01
0.01

54.34
45.64
0.02

Race, %
Caucasians
African Americans
Hispanic
Native Americans
Pacific Islanders
Asians
Others
N/A

74.46
17.35
2.16
0.39
0.06
0.98
2.31
2.29

78.28
13.48
1.93
0.50
0.07
1.05
2.12
2.56

73.97
17.84
2.20
0.37
0.06
0.96
2.34
2.24

1.36 (1.89)

1.72 (2.25)

1.29 (1.81)

42.52
25.35
14.68
17.45

36.85
24.88
15.45
22.82

43.61
25.41
14.52
16.45

Deyo-CCI, mean (SD)
Deyo-CCI categories, %
0
1
2
≥3

N/A = not available; Deyo-CCI = Deyo Charlson Comorbidity Index.
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Table 1. Characteristics of Hospitalized Patients With or Without Hyponatremia
(continued).
Patient Characteristics

Comorbidities, %
Hypertension
Myocardial Infarction
Coronary Artery Disease
Heart Failure
Diabetes Mellitus
Peripheral Vascular Disease
Chronic Kidney Disease
End Stage Renal Disease
Liver disease
Chronic Pulmonary disease
COPD
Adrenal Insufficiency
Hypothyroidism
Cerebrovascular disease
Hemiplegia/paraplegia
Rheumatologic disease
Depression
Dementia
AIDS
Malignancyb
Lung Cancer
Reasons for Hospitalization, %
Pneumonia
Sepsis
SIADH
Urinary Tract Infection

Normonatremia and Hyponatremia
All Cohorta
n= 2,488,437 patientsa (n=2,440,396)
Presence of
Absence of
Hyponatremia
Hyponatremia (≥135
(<135 mEq/L),
to ≤145 mEq/L),
n= 357,418
n=2,082,978
37.85
7.93
20.82
14.07
21.96
3.76
7.60
2.42
2.44
19.86
5.18
0.34
9.32
7.94
1.30
1.68
8.57
3.5
0.69
7.84
2.07

38.26
7.36
19.74
15.38
24.97
4.12
7.64
3.34
4.73
21.06
5.79
0.51
10.52
6.02
0.98
1.97
7.46
2.57
1.02
11.39
3.85

37.84
8.01
21.05
13.72
21.40
3.68
7.49
2.28
2.04
19.67
5.08
0.30
9.12
8.13
1.33
1.64
8.77
3.42
0.63
7.26
1.77

4.81
2.46
0.22
6.62

6.20
3.58
1.37
7.91

4.55
2.16
0.03
6.23

COPD = Chronic Obstructive Pulmonary Disease; AIDS = Acquired Immunodeficiency syndrome;
SIADH = Syndrome of Inappropriate Antidiuretic Hormone.
aSerum sodium levels corrected by adding 1.6 mEq/L for each 100 mg/dL above 100 mg/dL of

the concomitantly measured serum glucose levels. These number are before excluding the
patients with missing gender, race, or outcomes.
bExcept lung cancer
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Table 2. Factors Associated With Hyponatremia (<135 mEq/L)
Variables Included in the Model

Multivariate Logistic Regression
P value
Adjusted* OR (95%
CI)

Age (Ref: Age 18 to <45)
45 to <65
65 to <75
≥75
Comorbidities

1.21 (1.20-1.23)
1.35 (1.33-1.37)
1.56 (1.54-1.58)

<0.001
<0.001
<0.001

DM (Ref: No DM)

1.25 (1.24-1.26)

<0.001

ESRD (Ref: No ESRD)

1.50 (1.47-1.53)

<0.001

Chronic Liver Disease (Ref: No Chronic Liver
Disease
Cirrhosis (Ref: No Cirrhosis)

1.34 (1.28-1.39)

<0.001

2.67 (2.61-2.73)

<0.001

Adrenal Insufficiency (Ref: No Adrenal
Insufficiency)
AIDS (Ref: No AIDS)

1.44 (1.37-1.52)

<0.001

1.98 (1.90-2.05)

<0.001

Lung Cancer (Ref: No Lung Cancer)

1.47 (1.44-1.51)

<0.001

Pneumonia (Ref: No Pneumonia)

1.33 (1.31-1.35)

<0.001

Sepsis (Ref: No Sepsis)

1.59 (1.57-1.62)

<0.001

SIADH (Ref: No SIADH)

40.91 (37.68-44.41)

<0.001

UTI (Ref: No UTI)

1.30 (1.29-1.31)

<0.001

OR=Odds Ratio; Ref=Reference; DM=Diabetes Milletus; ESRD=End Stage Renal Disease; AIDS =
Acquired Immunodeficiency syndrome; SIADH = Syndrome of Inappropriate Antidiuretic
Hormone; UTI=Urinary Tract Infection.

*Adjusted for age, gender, race and the selected comorbidities.
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Furthermore, patients with DM, ESRD, chronic liver disease, cirrhosis, adrenal
insufficiency, AIDS, lung cancer, pneumonia, sepsis, SIADH, and UTI were
associated with a higher likelihood of developing hyponatremia (Table 2)
Low Serum Sodium Levels and the Outcomes:
The percentages of overall in-hospital mortality, discharge to hospice and
discharge to nursing facility were higher in the hyponatremia group than in the
normonatremia group (4.61%, 2.53% and 14.42% vs 2.46%, 1.22 % and 11.61%,
respectively), whereas discharge to home was higher in the normonatremia
group than in the hyponatremia group (64.82% vs 55.53%).
The crude probability of in-hospital mortality corresponding to the different serum
[Na] levels was lowest at serum [Na] levels between 135 and 143 mEq/L and
continued to increase above or below this range (Figure 2). The probability of
discharge to hospice demonstrated a similar pattern, though less profound. The
estimated probabilities of discharge to nursing facility also demonstrated a similar
pattern but started to decrease at serum [Na] levels below 115mEq/L. We
observed the opposite for discharge to home, such that the probability of this
outcome increased up to serum [Na] levels between 135 and 143mEq/L, then
decreased above this range (Figure 2).
For the serum [Na] categories we specified, the crude in-hospital mortality
increased as [Na] decreased or increased relative to the 138 to <140 mEq/L
interval (Table 3). This was also true for discharge to hospice and discharge to
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Figure 2. Restricted cubic splines of the crude estimated probability of in-hospital
mortality, discharge to hospice, discharge to home, and discharge to nursing facility as a
function of serum sodium levels at hospital admission. These estimated probabilities
were derived from a multinomial logistic regression model. Serum sodium levels were
corrected by adding 1.6 mEq/L for each 100 mg/dL above 100 mg/dL of the
concomitantly measured serum glucose levels.
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Table 3. Relationship between Serum Sodium levels at Hospital Admission and In-Hospital Mortality, Discharge to Hospice or to
Nursing Facility

Presence of
Hyponatremia (<135
mEq/L), n=334,318

Absence of Hyponatremia
(≥135 to ≤145 mEq/L),
n=1,950,594

Serum [Na] levelsa at
Hospital Admission
(mEq/L), n= 2,284,912

In-Hospital
Mortality,
n (%)
7,242 (5.4%)c

Adjustedb Relative Discharge to
Risk Ratio (95% CI) Hospice,
n (%)
2.15 (2.08-2.22)
2,981(2.2%)

Adjustedb Relative
Risk Ratio (95% CI)
1.91 (1.82-2.00)

Discharge to Nursing Facility
(n=274,755)
Discharge to
Adjustedb Relative
Nursing Facility,
Risk Ratio (95% CI)
n (%)
22,085 (16.4%)
1.36 (1.33-1.38)

15,112 (2.5%)

1 (reference)

7,082 (1.2%)

1 (reference)

71,770 (11.9%)

1 (reference)

138 to < 140
(n=601,610)

11,637 (1.9%)

0.78 (0.76-0.80)

5,997 (1%)

0.86 (0.83-0.89)

63,865 (10.6%)

0.97 (0.96-0.99)

135 to < 138
(n=611,947)

13,953 (2.3%)

0.90 (0.88-0.92)

7,809 (1.3%)

1.06 (1.03-1.10)

68,836 (11.2%)

1.08 (1.07-1.10)

130 to < 135
(n=280,970)

11,475 (4.1%)

1.45 (1.41-1.49)

6,369 (2.3%)

1.64 (1.58-1.70)

39,416 (14.0%)

1.26 (1.24-1.28)

125 to < 130
(n=41,953)
120 to < 125
(n=8,982)

2,941 (7.0%)

2.43 (2.32-2.54)

1,579 (3.8%)

2.56 (2.41-2.72)

7,038 (16.8%)

1.35 (1.31-1.39)

739 (8.2%)

3.12 (2.87-3.40)

408 (4.5%)

3.25 (2.91-3.63)

1,385 (15.4%)

1.21 (1.14-1.29)

< 120
(n=2,413)

260 (10.8%)

4.85 (4.20-5.60)

110 (4.6%)

3.71 (3.01-4.56)

360 (14.9%)

1.32 (1.16-1.49)

143 to ≤ 145
(n=134,979)
140 to < 143
(n=602,058)

In-Hospital Mortality (n=63,359)

Discharge to Hospice (n=32,335)

CI = confidence interval.
aSerum sodium levels corrected by adding 1.6 mEq/L for each 100 mg/dL above 100 mg/dL of the concomitantly measured serum glucose levels.
b

The adjusted relative risk ratios were derived from a multinomial logistic regression model adjusted for age, gender, race, and the selected
comorbidities (p<0.001 for all). Discharge to home is the referent outcome (n=1,739,780).

cThe percentages represent the percentage of each outcome within each serum sodium category.
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Figure 3. Forest plot of the relative risk ratios (95% CI) for in-hospital mortality, discharge to hospice, or discharge to nursing facility
associated with different intervals of serum sodium levels (mEq/L) at hospital admission. The relative risk ratios were derived from
multinomial logistic regression models adjusted for age, gender, race, and the selected comorbidities. Discharge to home and serum
sodium levels of (140 to <143 mEq/L) served as referent. Serum sodium levels were corrected by adding 1.6 mEq/L for each 100 mg/dL
increase above 100 mg/dL of the concomitantly measured serum glucose levels. Error bars indicated 95 % CI. CI = confidence interval.
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nursing facility. However, the percentage of discharge to nursing facility
decreased for the [Na] intervals 120 to <125 mEq/L and <120mEq/L (Table 3).
In the adjusted multinomial logistic regression analyses, we found that the
likelihood of in-hospital mortality increased for [Na] levels <135 mEq/L or ≥ 143 to
≤145 mEq/L compared to the reference interval of 140 to <143 mEq/L (p<0.001)
(Table 3, Figure 3). After adjusting for age, gender, race and the selected
comorbidities, patients with [Na] levels of <120, 120 to <125, 125 to <130, 130 to
<135, 135 to <138, 138 to <140 and 143 to ≤145 mEq/L compared with 140
to<143 mEq/L had in-hospital mortality relative risk ratios (RRRs) [95% CI] of
4.85 [4.20-5.60], 3.12 [2.87-3.40], 2.43 [2.32-2.54], 1.45 [1.41-1.49], 0.90 [0.880.92], 0.78 [0.76-0.80] and 2.15 [2.08-2.22] respectively (p<0.001 for all) (Table
3, Figure 3). This strong association with in-hospital mortality continued to rise
with the increase in the severity of hyponatremia. Patients with [Na] levels of 138
to <140 mEq/L had the lowest likelihood of in-hospital mortality. We observed
similar trends for the relationship between [Na] levels and discharge to hospice
or to a nursing facility (Table 3, Figure 3). We obtained very similar results after
adjusting for the Deyo-CCI instead of the selected comorbidities (Table 4, Figure
4).
Age and the Outcomes:
Using the method of restricted cubic splines, we observed that for low serum
[Na], the in-hospital mortality was higher for younger age groups compared to
older age groups. However, for [Na] levels within the normal range, the
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Table 4. Relationship between Serum Sodium levels at Hospital Admission and In-Hospital Mortality, Discharge to Hospice or
to Nursing Facility (Adjusting for the Deyo-CCI)

Presence of
Hyponatremia (<135
mEq/L), n=334,318

Absence of Hyponatremia
(≥135 to ≤145 mEq/L),
n=1,950,594

Serum [Na] levelsa at
Hospital Admission
(mEq/L), n= 2,284,912

In-Hospital Mortality (n=63,359)

Discharge to Hospice
(n=32,335)

Discharge to Nursing Facility
(n=274,755)

Adjustedb Relative Risk Ratio
(95% CI)
2.30 (2.23-2.36)

Adjustedb Relative Risk
Ratio (95% CI)
2.00 (1.91-2.09)

Adjustedb Relative Risk Ratio
(95% CI)
1.43 (1.40-1.46)

1 (reference)

1 (reference)

1 (reference)

138 to < 140
(n=601,610)

0.78 (0.76-0.79)

0.85 (0.82-0.88)

0.94 (0.93-0.96)

135 to < 138
(n=611,947)

0.91 (0.89-0.93)

1.04 (1.01-1.08)

1.04 (1.02-1.05)

130 to < 135
(n=280,970)

1.53 (1.50-1.57)

1.65 (1.59-1.70)

1.21 (1.19-1.23)

125 to < 130
(n=41,953)
120 to < 125
(n=8,982)

2.63 (2.52-2.74)

2.66 (2.51-2.82)

1.35 (1.31-1.39)

3.17 (2.93-3.44)

3.28 (2.95-3.66)

1.25 (1.18-1.33)

< 120
(n=2,413)

4.72 (4.11-5.41)

3.79 (3.09-4.64)

1.40 (1.24-1.58)

143 to ≤ 145
(n=134,979)
140 to < 143
(n=602,058)

CI = confidence interval; Deyo-CCI= Deyo-Charlson Comorbidity Index.
aSerum sodium levels corrected by adding 1.6 mEq/L for each 100 mg/dL above 100 mg/dL of the concomitantly measured serum glucose

levels.
bThe adjusted relative risk ratios were derived from a multinomial logistic regression model adjusted for age, gender, race, and the Deyo-

CCI (p<0.001 for all). Discharge to home is the referent outcome (n=1,739,780).
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Figure 4. Forest plot of the relative risk ratios (95% CI) for in-hospital mortality, discharge to hospice, or discharge to nursing facility
associated with different intervals of serum sodium levels (mEq/L) at hospital admission. The relative risk ratios were derived from
multinomial logistic regression models adjusted for age, gender, race, and Deyo-CCI. Discharge to home and serum sodium levels of
(140 to <143 mEq/L) served as referent. Serum sodium levels were corrected by adding 1.6 mEq/L for each 100 mg/dL increase above
100 mg/dL of the concomitantly measured serum glucose levels. Error bars indicated 95 % CI. CI = confidence interval; Deyo-CCI =
Deyo Charlson Comorbidity Index.
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in-hospital mortality was higher for older age groups compared to younger age
groups (Figure 5). Older age groups had a higher probability of discharge to
hospice at normal serum [Na] than younger age groups. However, as serum [Na]
decreased, the probability of discharge to hospice for the youngest (18 to <45)
and oldest (≥75) age groups, was lower than that for the middle age groups (age
45 to <65 and 65 to <75) (Figure 6).
For discharge to nursing facility, older age groups had higher estimated
probabilities compared to younger age groups for all [Na] levels (Figure 7). For
discharge to home, for normal [Na] levels, the probability for discharge to home
was higher in the younger age groups compared to older age groups. However,
as the serum [Na] levels decreased, discharge to home was higher in the older
age groups compared to the younger age groups (Figure 8).
We obtained similar findings after modeling the interaction of each age group
with the different [Na] categories and after adjusting for age, gender, race and
the selected comorbidities (Figure 9, Table 5). We compared the relative risk
ratios (RRRs) for in-hospital mortality associated with the [Na] categories
between the different age groupings from the model that included the age by [Na]
interation (Figure 9, Table 5) using linear combinations of coefficients estimation
(Table 6). We noted that for [Na] <130 mEq/L and ≥143 to ≤145 mEq/L, the
relative risk ratios (RRRs) for in-hospital mortality were significantly greater for
each age group compared to the consecutive older age group, except for ages
≥65 to <75 and ≥ 75 in the [Na] category of <120 mEq/L, ≥18 to <45 and 45 to
<65 in the [Na] category of 120 to <125 mEq/L, and ≥65 to
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Figure 5. Restricted cubic splines of the estimated probability of in-hospital mortality as
a function of serum sodium levels for different age groups. These estimated
probabilities were derived from a multinomial logistic regression models stratifies by
age.
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Figure 6. Restricted cubic splines of the estimated probability of discharge to hospice as
a function of serum sodium levels for different age groups. These estimated
probabilities were derived from a multinomial logistic regression models stratifies by
age.
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Figure 7. Restricted cubic splines of the estimated probability of discharge to nursing
facility as a function of serum sodium levels for different age groups. These estimated
probabilities were derived from a multinomial logistic regression models stratifies by
age.
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Figure 8. Restricted cubic splines of the estimated probability of discharge to home as a
function of serum sodium levels for different age groups. These estimated probabilities
were derived from a multinomial logistic regression models stratifies by age.
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Figure 9. Forest plot of the relative risk ratios (95% CI) for in-hospital mortality associated with different intervals of serum sodium
levels (mEq/L) at hospital admission for the different age groups. The relative risk ratios were derived from multinomial logistic
regression models adjusted for age, gender, race, and the selected comorbidities. Serum sodium levels of (140 to <143 mEq/L)
served as referent and each age group served as its own referent. Serum sodium levels were corrected by adding 1.6 mEq/L for each
100 mg/dL increase above 100 mg/dL of the concomitantly measured serum glucose levels. Error bars indicated 95 % CI. CI =
confidence interval. p<0.001 for all except for age 65 to <75 in the 135 to <138 mEq/L category (p=0.43).
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Table 5. In-hospital Mortality Associated With Different Intervals of Serum [Na] levels for the Different Age Groups.
Final Cohort,
n= 2,284,912
Age groups
Age 18 to <45
(n=461,511)
Mortality, n (%)
Adjusted RRRb
(95% CI)
Age 45 to <65
(n=740,035)
Mortality, n (%)
Adjusted RRR
(95% CI)
Age 65 to <75
(n=404,848)
Mortality, n (%)
Adjusted RRR
(95% CI)
Age ≥75
(n=678,518)
Mortality, n (%)
Adjusted RRR
(95% CI)
Total mortality,
n (%)

Serum Sodium Categories, mEq/L
< 120
(n=2,413)
n=209

120 to <125
(n=8,982)
n=657

125 to < 130
(n=41,953)
n=3,675

130 to < 135
(n=280,970)
n=47,147

135 to < 138
(n=611,947)
n=142,670

138 to < 140
(n=601,610)
n=134,810

140 to < 143
(n=602,058)
n=112,739

143 to ≤ 145
(n=134,979)
n=19,604

27 (12.9%)a
15.3 (9.6-24.3)

43 (6.5%)
6.7 (4.8-9.5)

208 (5.7%)
5.6 (4.7-6.7)

622 (1.3%)
1.6 (1.4-1.7)

431 (2.2%)
3.3 (2.9-3.7)

n=2,989

n=12,811

n=89,157

591 (0.4%)
0.64 (0.570.71)
n=200,104

758 (0.7%)
1 (Reference)

n=905

794 (0.6%)
0.76 (0.690.84)
n=199,810

n=194,784

n=39,475

116 (12.8%)

281 (9.4 %)

965 (7.5%)

3,256 (3.6%)

3,402 (1.7%)

2,717 (1.4%)

3,135 (1.6%)

1,517 (3.8%)

7.4 (5.9-9.2)

5.0 (4.3-5.7)

3.5 (3.3-3.8)

1.7 (1.7-1.8)

2.4 (2.2-2.5)

n=1,719

n=8,468

n=52,649

0.81 (0.770.85)
n=103,702

1 (Reference)

n=433

0.93 (0.880.97)
n=104,535

n=108,698

n=24,644

36 (8.3%)
3.4 (2.3-4.9)

148 (8.6%)
3.1 (2.6-3.8)

612 (7.2%)
2.4 (2.2-2.7)

2,546 (4.8%)
1.6 (1.5-1.7)

1,313 (5.3%)
2.1 (1.9-2.2)

n=3,617

n=16,999

n=92,017

2,449 (2.4%)
0.83 (0.790.88)
n=162,994

2,949 (2.7%)
1 (Reference)

n=866

3,009 (2.9%)
0.98 (0.931.03)c
n=164,932

n=185,837

n=51,256

81 (9.3%)
3.0 (2.3-3.9)

267 (7.4%)
2.0 (1.7-2.3)

1,156 (6.8%)
1.7 (1.6-1.8)

5,051 (5.5%)
1.2 (1.2-1.3)

3,981 (7.8%)
2.0 (1.9-2.0)

739 (8.2%)

2,941 (7.0%)

11,475 (4.0%)

5,880 (3.6%)
0.78 (0.760.81)
11,637 (1.9%)

8,270 (4.4%)
1 (Reference)

260 (10.8%)

6,748 (4.1%)
0.89 (0.860.92)
13,953 (2.3%)

15,112 (2.5%)

7,242 (5.4%)

aThe percentages and the relative risk ratios

RRR of in-hospital mortality are within(for) each age group with the respective serum [Na] category.

bThe relative risk ratios (RRRs) are derived from a multinomial logistic regression model adjusted for age, gender, race, and the

CI=Confidence interval. p<0.001 for all except: c

p=0.45.
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selected comorbidities.

Table 6. Comparisons of the Relative Risk Ratios of In-Hospital Mortality Associated With the Different Serum Sodium Interval for the
Different Age Groups.
Age groups
comparisons

<120 mEq/L

120 to <125 mEq/L

125 to<130 mEq/L

130 to <135 mEq/L

RRR
P value RRR
P value RRR
P value RRR
P value
(95% CI)
(95% CI)
(95% CI)
(95% CI)
Age0-Age1
2.07(1.24 0.005
1.34(0.93 0.12
1.58(1.31 <0.001 0.89(0.79 0.07
-3.46)
-1.95)
-1.91)
-1.01)
Age1- Age2
2.19(1.43 <0.001 1.58(1.25 <0.001 1.46(1.29 <0.001 1.11(1.03 0.005
-3.37)
-2.00)
-1.66)
-1.20)
Age 2-Age3
1.11(0.71 0.64
1.58(1.25 <0.001 1.42(1.26 <0.001 1.26(1.18 <0.001
-1.74)
-2.00)
-1.60)
-1.35)
Age0-Age2
4.55(2.51 <0.001 2.13(1.44 <0.001 2.32(1.91 <0.001 1.00(0.88 0.96
-8.24)
-3.14)
-2.82)
-1.13)
Age0-Age3
5.07(3.00 <0.001 3.36(2.33 <0.001 3.30(2.75 <0.001 1.26(1.12 <0.001
-8.58
-4.87)
-3.96)
-1.41)
Age1-Age3
2.44(1.75 <0.001 2.50(2.06 <0.001 2.08(1.87 <0.001 1.41(1.32 <0.001
-3.40)
-3.04)
-2.31)
-1.50)
RRR=Relative Risk Ratio;
Age0=Age (≥18 to <45); Age1=Age (≥45 to <65); Age2=Age (≥65 to <75); Age3=Age ≥75.
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135 to <138 mEq/L

138 to <140 mEq/L

143 to ≤145 mEq/L

RRR
(95% CI)
0.82(0.73
-0.91)
0.95(0.88
-1.02)
1.10(1.03
-1.17)
0.78(0.69
-0.87)
0.85(0.76
-0.95)
1.04(0.98
-1.11)

RRR
(95% CI)
0.79(0.70
-0.89)
0.97(0.90
-1.05)
1.06(0.99
-1.13)
0.77(0.68
-0.87)
0.81(0.73
-0.91)
1.03(0.97
-1.10)

RRR
(95% CI)
1.38(1.20
-1.58)
1.14(1.04
-1.26)
1.05(0.97
-1.14)
1.57(1.36
-1.81)
1.65(1.45
-1.88)
1.20(1.11
-1.30)

P value
<0.001
0.19
0.005
<0.001
0.003
0.18

P value
<0.001
0.45
0.07
<0.001
<0.001
0.35

P value
<0.001
0.007
0.24
<0.001
<0.001
<0.001

<75 and ≥ 75 in the [Na] category of 143 to ≤145 mEq/L. The difference was not
statistically significant. However, for 135 to <138 and 138 to <140 mEq/L [Na]
categories, the relative risk ratios (RRRs) for in-hospital mortality were
significantly lower in the 18 to <45 age groups compared to all other older age
groups. We obtained similar finding after adjusting for Deyo-CCI instead of the
comorbidities (data not shown).
In-Hospital Mortality in Other Patient Subgroups
We compared in-hospital mortality among the different patient’s subgroups with
or without hyponatremia. We found that patients with HIV, depression, chronic
kidney disease, coronary artery disease, metastatic cancer and any malignancy
(except lung cancer) had a higher likelihood of in-hospital mortality compared to
patients with the same comorbidities but without hyponatremia (Figure 10).
Although we opted to use the 1.6 correction factor, repeating the analysis without
any adjustments for concomitant glucose or after adding 2.4 mEq/L (38) resulted
in similar conclusions (data not shown).
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Figure 10. Forest plot of the odds ratios (95% CI) for the comparison of in-hospital mortality in different subgroups of patients with versus
without serum sodium levels of <135 mEq/L. The odds ratios were derived from logistic regression models adjusted for age, gender, race, and
the selected comorbidities of the patients. The P values for interaction between serum sodium levels <135 mEq/L and the different subgroup
mentioned above are as follows: Coronary artery disease 0.02, heart failure 0.47, diabetes mellitus 0.07, peripheral vascular disease 0.03,
chronic kidney disease <0.001, end stage renal disease <0.001, cirrhosis 0.81, COPD <0.001, cerebrovascular disease <0.001, adrenal
insufficiency 0.05, hypothyroidism 0.003, depression 0.02, HIV 0.002, metastatic cancer 0.01, lung cancer <0.001, malignancy <0.001, pneumonia
<0.001, sepsis <0.001, SIADH <0.001, and urinary tract infection <0.001.
* Any malignancy except lung cancer
COPD=chronic obstructive pulmonary disease; HIV=human immunodeficiency virus; SIADH=syndrome of inappropriate antidiuretic hormone
secretion.
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CHAPTER 4
DISCUSSION

In this observational study using a large multicenter database, we were able to
demonstrate using the cutoff point of <135 mEq/L that the prevalence of
hyponatremia was common at hospital admission (14.4%). We showed that
having [Na] levels < 135 mEq/L or ≥ 143 to ≤145 mEq/L is an independent risk
factor for in-hospital mortality and increased discharge to hospice or to a nursing
facility. Moreover, we found that younger patients admitted with [Na] levels <130
mEq/L or ≥143 to ≤ 145 mEq/L had a higher risk of in-hospital mortality
compared to older patients.
In general, our results corroborate those of several other investigators. For
example, Waikar et al (7) reported that the prevalence of hyponatremia at
hospital admission in two teaching hospitals with 98,411 patients was 14.5 %
and in another study by Holland-bill et al (17), which included 279,508
hospitalized patients, using the same cutoff point of <135 mEq/L the prevalence
was 15 %. In another study by Wald et al, which included 53,236 adult
hospitalizations, the prevalence of hyponatremia at hospital admission was
higher (38%) (8). However, using the same cutoff point used by Wald et al (<138
mEq/L) yielded a very similar prevalence (40.56%).
Our results are in accordance to previous studies showing that hyponatremia is
an independent risk factor for in-hospital mortality (7, 8, 17). Moreover, we
documented an independent association between hyponatremia and the
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increased risk of discharge to hospice or to a nursing facility. Furthermore, we
demonstrated that the in-hospital mortality continues to worsen with the increase
in the severity of hyponatremia, a conclusion that was also reached by Wald et al
(8). However, this conclusion is at odds with the findings of Holland-bill et al (17).
In that study the risk of mortality increased as the [Na] levels decreased;
however, when [Na] values dropped to <132 mEq/L there was no further increase
in mortality. Also our results are in disagreement with the findings of study by
Chawla et al that included 45,693 hospitalized patients from a single hospital
between 1996 and 2007. In this study, the in-hospital mortality increased as [Na]
decreased from 134 to 120 mEq/L (16). However, there was an opposite pattern
for [Na] below 120 mEq/L were the mortality rate decreased progressively.
Although in the present study the risk of in-hospital mortality was the lowest in
the 138 to <140 mEq/L group, the in-hospital mortality for the 135 to < 138 mEq/L
group was still low compared to the other [Na] categories. Our results support the
traditional lower cutoff point of normonatremia of 135 mEq/L. Realizing that the
risk of in-hospital mortality intensified for values ≥ 143 to ≤145 mEq/L, we support
the proposition expressed by Wald et al that the traditional higher cutoff point of
normonatremia (≤145 mEq/L) needs to be reevaluated. Based on our own
findings reported herein, we advocate the use of < 143 mEq/L as a higher cutoff
point for normonatremia.
We demonstrated that the likelihood of in-hospital mortality associated with [Na]
levels varied between the various age groups. Younger age groups (≥18 to <45
years and ≥45 to <65 years) had higher likelihood of in-hospital mortality
37

compared to older age groups (≥65 to <75 years, ≥75 years) for [Na] levels <130
mEq/L or ≥143 to ≤ 145 mEq/L. It is the contention of some investigators that
elderly patients have a high risk of mortality at hospital admission (22-24).
However, other investigators do not agree with this position (25, 26). In a
retrospective study by Ganguli and colleagues that included 608 elderly
participants aged >65 years in a home-based primary care program, it was found
that hyponatremia was independently associated with falls, fractures,
hospitalizations but not mortality (26). In a case control study by Ahamed et al,
including patients aged ≥ 65 years old admitted to the hospital during a 6 months
period, hyponatremia was independently associated with admission-associated
falls and increased length of hospital stay but was not associated with increased
risk of mortality (25). Moreover, Wald et al (8) compared the mortality rates of
patients younger than 65 years old versus patients who were at least 65 years
old and found that the in-hospital mortality rate was higher in younger patients
compared to older patients.
The differential association between hyponatremia and mortality in the different
age groups has several plausible explanations. It is well known that chronic
hyponatremia (>48 hours) is very common in elderly population: chronic
hyponatremia is present in 11.3 % of elderly people living in the community (18)
and 18% of the elderly residing in nursing home facilities (19). In chronic
hyponatremia, adaptation mechanisms in the brain render patients less prone to
the development of brain herniation. Moreover, the possibility of developing
osmotic demyelination after the correction of chronic hyponatremia is rare and
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less likely if the hyponatremia is corrected slowly (39). The other possible
explanation is the difference in the ratio of the brain size to the cranial vault
between elderly patients and younger patients. The high ratio of the size of the
brain to the cranial vault in children has been postulated to play and important
role in impeding brain adaptation mechanisms and leading to the observed
increased mortality for those with hyponatremia (40). Hence, it is believed that
the decrease in brain volume due to brain atrophy in the elderly plays a
protective role against the sequelae of hyponatremic encephalopathy (41). In
contrast, younger patients probably suffer from acute hyponatremia which
develops over the course of few hours and most probably die from cerebral
edema and brain herniation (39). Due to the inhibitory effects of estrogen on the
brain adaptation to hyponatremia, menstruating women have 25 times higher risk
of death or permanent neurological damage from hyponatremic encephalopathy
than postmenopausal women (41). Furthermore, younger patients are more likely
to engage in risky behaviors such as ecstasy use (42) and marathon running (43)
that are linked to fatal complications of hyponatremia.
Our study has several strengths. The size of our study allowed us to robustly
investigate the association between the different levels of hyponatremia and
selected outcomes of hospitalized patients even with very low levels of
hyponatremia. For example, for patients with serum sodium levels < 120 mEq/L
the number of deaths was 260 out of 2413, which, to our knowledge, is higher
than that found in any other published report. Our cohort included a diverse
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patient population from many hospitals in the United States, hence our results
are generalizable to the US population.
Our study had several limitations. First, inherent in our study was the use of ICD9 codes to identify patients’ comorbidities, which is prone to billing and coding
errors. However, the Health Facts data undergo extensive review before being
added to the database. Second, we based our interpretation of the relationship
between in-hospital mortality due to hyponatremia and age on the assumption
that chronic hyponatremia is common in older patients and acute hyponatremia is
common in younger patients. We did not have the [Na] data in the outpatient
setting which is very important to distinguish chronic from acute hyponatremia.
Third, we also did not have the information about the use of the outpatient
medications that predispose to the development of hyponatremia. Including the
data about these medications would enhance the information provided in our
study. Moreover, confirming that the elderly patients in our study are in fact
taking the medications that are known to cause chronic hyponatremia will make
us more comfortable in stating our assumption that chronic hyponatremia was
more common in these patients. Nevertheless, we believe that accounting for the
real causes of hyponatremia or determining the exact mechanism for the
association between hyponatremia and in-hospital mortality should not distract us
from the important finding in our study that hyponatremia, regardless of the
cause, is independently associated with increased in-hospital mortality. Finally,
because of the observational nature of our study we cannot preclude the
possibility of residual confounding and cannot draw any causal interpretations
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from our results. However, conducting large randomized controlled trails (RCT) to
overcome this limitation may not be feasible.
CONCLUSIONS
Hyponatremia is common among hospitalized patients and regardless of the
cause, it contributes significantly to the morbidity and mortality of hospitalized
patients. It is an independent risk factor for increased in-hospital mortality and
increased discharge to hospice or to nursing facility. Moreover, younger patients
admitted with hyponatremia had a higher risk of in-hospital mortality compared to
older patients. Our study underscores the need for more alertness to the [Na]
levels in the outpatient setting and emphasizes the need for providing equal
attention and care to all patients presenting to hospital with hyponatremia. Our
next step would be to test whether the optimal correction of hyponatremia would
improve the outcomes of hospitalized patients.
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